FAST NEWS: Henlius Biotech’s annual sales double, but loss widens in second half
The latest: Shanghai Henlius Biotech Inc. (2696.HK) reported last Friday its revenue soared 91.1% to 3.21 billion yuan ($466 million) last year, while its annual net loss narrowed 29.4% to…
FAST NEWS: Antengene Invests $36 Million in Drug Discovery Center
The latest: Biopharma company Antengene Corp. Ltd. (6996.HK) announced Monday it has entered into an agreement with a contractor to build a drug discovery and manufacturing center for antibody biologics in…
FAST NEWS: Antengene Corporation Announces First Ever Revenue of $7.8 Million
The latest: Antengene Corp. Ltd. (6996.HK), a biopharmaceutical company, announced Thursday it expects revenue for the six months ended June 30 this year to range from 53 million yuan ($7.8…
RELATED ARTICLES
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK -
Fosun moves on from debt crisis with renewed focus on tourism, healthcare
0656.HK
-
Yalla revenue growth returns to double-digits ahead of new gaming push
YALA.US
-
BRIEF: Shanghai Chicmax’s profit surges nearly 70%, growth slows in second half
2145.HK
-
Rebounding RLX plots course beyond China
RLX.US
-
Fenbi chalks up loss as edtech scrambles into AI
2469.HK
